专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5944753A Medicament coated refractive anterior chamber ocular implant 失效
$Medicament coated refractive anterior chamber ocular implant$
公开(公告)号：US5944753A
公开(公告)日：1999-08-31
申请号：US815895
申请日：1997-03-12
申请人： Miles A. Galin , Joseph C. Salamone , Stanley C. Israel
发明人： Miles A. Galin , Joseph C. Salamone , Stanley C. Israel
IPC分类号： A61F2/14 , A61L27/00 , A61L27/34 , A61L33/00 , A61F2/16
CPC分类号： A61F2/1605 , A61F2/147 , A61L27/34 , A61L33/0011 , A61L33/0094 , A61L2430/16 , Y10S623/901
摘要： A minus power anterior chamber ocular implant for placement in the anterior chamber of a phakic eye having an anatomic lens in situ comprises a negative artificial refracting lens having at least one concave surface, a surface coating which comprises a compatible sulfated polysaccharide medicament coating, such as heparin, and having a structure which positions the artificial lens in the anterior chamber of the eye to prevent contact between the implant and the anatomic lens. The implant compensates for refractive errors or creates a specific refraction to assist in visual function and has increased biocompatibility in the anterior chamber of the eye, thereby preventing or mitigating detrimental effects typically associated with the implantation of an uncoated refractive anterior chamber implant in the eye. A method of preparing such a minus power anterior chamber ocular implant comprises first exposing an uncoated implant to a plasma to generate a plasma-treated implant having a surface containing amines, carboxylic acids, active free radicals or passive free radicals, and thereafter bonding the medicament to the plasma-treated implant surface. A method of treating myopia comprises surgically implanting and anchoring the implant in the phakic eye to compensate for refractive errors.

2. 发明授权

US5612027A Controlled release of miotic and mydriatic drugs in the anterior chamber 失效
标题翻译：在前房中控制释放弥漫性和散瞳药物
公开(公告)号：US5612027A
公开(公告)日：1997-03-18
申请号：US423703
申请日：1995-04-18
申请人： Miles A. Galin , Joseph C. Salamone , Stanley C. Israel
发明人： Miles A. Galin , Joseph C. Salamone , Stanley C. Israel
IPC分类号： A61K9/107 , A61F9/00 , A61K9/00 , A61K9/50 , A61K31/137 , A61K31/165 , A61K31/221 , A61K31/415 , A61K31/4178 , A61K31/46 , A61K31/715 , A61K31/728 , A61K31/74 , A61K31/765 , A61K45/00 , A61K47/30 , A61L31/04 , A61P27/02 , A61P27/06 , A61P27/08
CPC分类号： A61L31/048 , A61K31/137 , A61K31/221 , A61K31/4178 , A61K31/46 , A61K31/728 , A61K31/765 , A61K9/0048 , A61F9/00 , Y10S514/912
摘要： The present invention relates to compositions which maintain the structural integrity of the anterior chamber of the eye during ophthalmologic surgery, thereby protecting the tissues that form and line the anterior segment from potential damage and simultaneously providing sustained delivery of a miotic or mydriatic agent. The present invention provides for compositions which comprise a viscoelastic polymer, wherein sustained release of a miotic or mydriatic agent is mediated by ionic interactions, as well as for compositions wherein sustained release of a miotic or mydriatic agent is mediated by microcapsules or copolymer micelles.
摘要翻译：本发明涉及在眼科手术期间保持眼睛前房的结构完整性的组合物，从而保护形成和排出前节段的组织免受潜在的损伤并同时提供缩瞳剂或散瞳剂的持续递送。本发明提供了包含粘弹性聚合物的组合物，其中缩瞳剂或散瞳剂的持续释放是通过离子相互作用介导的，以及其中微型或散瞳剂的持续释放由微胶囊或共聚物胶束介导的组合物。

3. 发明授权

US5759532A Controlled release of miotic and myriatic drugs in the anterior chamber 失效
标题翻译：瞳孔和神经麻醉药物在前房的控制释放
公开(公告)号：US5759532A
公开(公告)日：1998-06-02
申请号：US815213
申请日：1997-03-12
申请人： Miles A. Galin , Joseph C. Salamone , Stanley C. Israel
发明人： Miles A. Galin , Joseph C. Salamone , Stanley C. Israel
IPC分类号： A61K9/107 , A61F9/00 , A61K9/00 , A61K9/50 , A61K31/137 , A61K31/165 , A61K31/221 , A61K31/415 , A61K31/4178 , A61K31/46 , A61K31/715 , A61K31/728 , A61K31/74 , A61K31/765 , A61K45/00 , A61K47/30 , A61L31/04 , A61P27/02 , A61P27/06 , A61P27/08
CPC分类号： A61L31/048 , A61K31/137 , A61K31/221 , A61K31/4178 , A61K31/46 , A61K31/728 , A61K31/765 , A61K9/0048 , A61F9/00 , Y10S514/912
摘要： The present invention relates to compositions which maintain the structural integrity of the anterior chamber of the eye during ophthalmologic surgery, thereby protecting the tissues that form and line the anterior segment from potential damage and simultaneously providing sustained delivery of a miotic or mydriatic agent. The present invention provides for compositions which comprise a viscoelastic polymer, wherein sustained release of a miotic or mydriatic agent is mediated by ionic interactions, as well as for compositions wherein sustained release of a miotic or mydriatic agent is mediated by microcapsules or copolymer micelles.
摘要翻译：本发明涉及在眼科手术期间保持眼睛前房的结构完整性的组合物，从而保护形成和排出前节段的组织免受潜在的损伤并同时提供缩瞳剂或散瞳剂的持续递送。本发明提供了包含粘弹性聚合物的组合物，其中缩瞳剂或散瞳剂的持续释放是通过离子相互作用介导的，以及其中微型或散瞳剂的持续释放由微胶囊或共聚物胶束介导的组合物。

4. 发明授权

US5652014A Medicament coated refractive anterior chamber ocular implant 失效
$Medicament coated refractive anterior chamber ocular implant$
标题翻译：药物涂层折叠前房眼植入物
公开(公告)号：US5652014A
公开(公告)日：1997-07-29
申请号：US193160
申请日：1994-08-25
申请人： Miles A. Galin , Joseph C. Salamone , Stanley C. Israel
发明人： Miles A. Galin , Joseph C. Salamone , Stanley C. Israel
IPC分类号： A61F2/14 , A61L27/00 , A61L27/34 , A61L33/00 , A61F2/16
CPC分类号： A61F2/1605 , A61F2/147 , A61L27/34 , A61L33/0011 , A61L33/0094 , A61L2430/16 , Y10S623/901
摘要： A minus power anterior chamber ocular implant for placement in the anterior chamber of a phakic eye having an anatomic lens in situ comprises a negative artificial refracting lens having at least one concave surface, a surface coating which comprises a compatible sulfated polysaccharide medicament coating, such as heparin, and and having a structure which positions having a structure which positions the artificial lens in the anterior chamber of the eye to prevent contact between the implant and the anatomic lens. The implant compensates for refractive errors or creates a specific refraction to assist in visual function and has increased biocompatibility in the anterior chamber of the eye, thereby preventing or mitigating detrimental effects typically associated with the implantation of an uncoated refractive anterior chamber implant in the eye. A method of preparing such a minus power anterior chamber ocular implant comprises first exposing an uncoated implant to a plasma to generate a plasma-treated implant having a surface containing amines, carboxylic acids, active free radicals or passive free radicals, and thereafter bonding the medicament to the plasma-treated implant surface. A method of treating myopia comprises surgically implanting and anchoring the implant in the phakic eye to compensate for refractive errors.
摘要翻译： PCT No.PCT / US92 / 06818 Sec。 371日期：1994年8月25日 102（e）日期1994年8月25日PCT提交1992年8月13日PCT公布。公开号WO93 / 03776 日期1993年3月4日一种用于放置在具有解剖镜片的晶状体眼的前房中的负功率前房眼植入物包括具有至少一个凹表面的负人造折射透镜，包含相容的硫酸化多糖的表面涂层药物包衣，例如肝素，并且具有将人造镜片定位在眼前房中的结构的结构，以防止植入物和解剖镜片之间的接触。植入物补偿屈光不正或产生特定折射以辅助视觉功能，并且增加眼睛前房中的生物相容性，从而防止或减轻通常与眼睛中未涂覆的折射性前房植入物植入有关的有害影响。制备这种负电源前房眼植入物的方法包括首先将未涂覆的植入物暴露于等离子体以产生具有包含胺，羧酸，活性自由基或被动自由基的表面的等离子体处理的植入物，然后将药物到等离子体处理的植入物表面。治疗近视的方法包括将植入物手术植入和固定在晶状体眼中以补偿屈光不正。

5. 发明授权

US6143028A Medicament coated refractive anterior chamber ocular implant 失效
$Medicament coated refractive anterior chamber ocular implant$
标题翻译：药物涂层折叠前房眼植入物
公开(公告)号：US6143028A
公开(公告)日：2000-11-07
申请号：US063624
申请日：1998-04-20
申请人： Miles A. Galin , Joseph C. Salamone , Stanley C. Israel
发明人： Miles A. Galin , Joseph C. Salamone , Stanley C. Israel
IPC分类号： A61F2/14 , A61L27/00 , A61L27/34 , A61L33/00 , A61F2/16
CPC分类号： A61F2/1605 , A61F2/147 , A61L27/34 , A61L33/0011 , A61L33/0094 , A61L2430/16 , Y10S623/901
摘要： A minus power anterior chamber ocular implant for placement in the anterior chamber of a phakic eye having an anatomic lens in situ comprises a negative artificial refracting lens having at least one concave surface, a surface coating which comprises a compatible sulfated polysaccharide medicament coating, such as heparin, and having a structure which positions the artificial lens in the anterior chamber of the eye to prevent contact between the implant and the anatomic lens. The implant compensates for refractive errors or creates a specific refraction to assist in visual function and has increased biocompatibility in the anterior chamber of the eye, thereby preventing or mitigating detrimental effects typically associated with the implantation of an uncoated refractive anterior chamber implant in the eye. A method of preparing such a minus power anterior chamber ocular implant comprises first exposing an uncoated implant to a plasma to generate a plasma-treated implant having a surface containing amines, carboxylic acids, active free radicals or passive free radicals, and thereafter bonding the medicament to the plasma-treated implant surface. A method of treating myopia comprises surgically implanting and anchoring the implant in the phakic eye to compensate for refractive errors.
摘要翻译：用于放置在具有解剖镜片的晶状体眼的前房中的负功率前房眼植入物包括具有至少一个凹表面的负人造折射透镜，包含相容的硫酸化多糖药物涂层的表面涂层，例如肝素，并且具有将人造镜片定位在眼睛前房中以防止植入物和解剖镜片之间接触的结构。植入物补偿屈光不正或产生特定折射以辅助视觉功能，并且增加眼睛前房中的生物相容性，从而防止或减轻通常与眼睛中未涂覆的折射性前房植入物植入有关的有害影响。制备这种负电源前房眼植入物的方法包括首先将未涂覆的植入物暴露于等离子体以产生具有包含胺，羧酸，活性自由基或被动自由基的表面的等离子体处理的植入物，然后将药物到等离子体处理的植入物表面。治疗近视的方法包括将植入物手术植入和固定在晶状体眼中以补偿屈光不正。

6. 发明授权

US5965152A Controlled release of miotic and mydriatic drugs in the anterior chamber 失效
标题翻译：在前房中控制释放弥漫性和散瞳药物
公开(公告)号：US5965152A
公开(公告)日：1999-10-12
申请号：US815896
申请日：1997-03-12
申请人： Miles A. Galin , Joseph C. Salamone , Stanley C. Israel
发明人： Miles A. Galin , Joseph C. Salamone , Stanley C. Israel
IPC分类号： A61K9/107 , A61F9/00 , A61K9/00 , A61K9/50 , A61K31/137 , A61K31/165 , A61K31/221 , A61K31/415 , A61K31/4178 , A61K31/46 , A61K31/715 , A61K31/728 , A61K31/74 , A61K31/765 , A61K45/00 , A61K47/30 , A61L31/04 , A61P27/02 , A61P27/06 , A61P27/08 , A61F2/00 , A61K9/14
CPC分类号： A61L31/048 , A61K31/137 , A61K31/221 , A61K31/4178 , A61K31/46 , A61K31/728 , A61K31/765 , A61K9/0048 , A61F9/00 , Y10S514/912
摘要： The present invention relates to compositions which maintain the structural integrity of the anterior chamber of the eye during ophthalmologic surgery, thereby protecting the tissues that form and line the anterior segment from potential damage and simultaneously providing sustained delivery of a miotic or mydriatic agent. The present invention provides for compositions which comprise a viscoelastic polymer, wherein sustained release of a miotic or mydriatic agent is mediated by ionic interactions, as well as for compositions wherein sustained release of a miotic or mydriatic agent is mediated by microcapsules or copolymer micelles.
摘要翻译：本发明涉及在眼科手术期间保持眼睛前房的结构完整性的组合物，从而保护形成和排出前节段的组织免受潜在的损伤并同时提供缩瞳剂或散瞳剂的持续递送。本发明提供了包含粘弹性聚合物的组合物，其中缩瞳剂或散瞳剂的持续释放是通过离子相互作用介导的，以及其中微型或散瞳剂的持续释放由微胶囊或共聚物胶束介导的组合物。

7. 发明授权

US5766580A Controlled release of miotic and mydriatic drugs in the anterior chamber 失效
公开(公告)号：US5766580A
公开(公告)日：1998-06-16
申请号：US815215
申请日：1997-03-12
申请人： Miles A. Galin , Joseph C. Salamone , Stanley C. Israel
发明人： Miles A. Galin , Joseph C. Salamone , Stanley C. Israel
IPC分类号： A61K9/107 , A61F9/00 , A61K9/00 , A61K9/50 , A61K31/137 , A61K31/165 , A61K31/221 , A61K31/415 , A61K31/4178 , A61K31/46 , A61K31/715 , A61K31/728 , A61K31/74 , A61K31/765 , A61K45/00 , A61K47/30 , A61L31/04 , A61P27/02 , A61P27/06 , A61P27/08
CPC分类号： A61L31/048 , A61K31/137 , A61K31/221 , A61K31/4178 , A61K31/46 , A61K31/728 , A61K31/765 , A61K9/0048 , A61F9/00 , Y10S514/912
摘要： The present invention relates to compositions which maintain the structural integrity of the anterior chamber of the eye during ophthalmologic surgery, thereby protecting the tissues that form and line the anterior segment from potential damage and simultaneously providing sustained delivery of a miotic or mydriatic agent. The present invention provides for compositions which comprise a viscoelastic polymer, wherein sustained release of a miotic or mydriatic agent is mediated by ionic interactions, as well as for compositions wherein sustained release of a miotic or mydriatic agent is mediated by microcapsules or copolymer micelles.

8. 发明授权

US5972326A Controlled release of pharmaceuticals in the anterior chamber of the eye 失效
标题翻译：药物在眼前房的控制释放
公开(公告)号：US5972326A
公开(公告)日：1999-10-26
申请号：US819255
申请日：1997-03-18
申请人： Miles A. Galin , Joseph C. Salamone , Stanley C. Israel
发明人： Miles A. Galin , Joseph C. Salamone , Stanley C. Israel
IPC分类号： A61F2/14 , A61F9/00 , A61K9/00 , A61K31/137 , A61K31/221 , A61K31/4178 , A61K31/46 , A61K31/728 , A61K31/765 , A61L31/04 , A61L31/16 , A61K31/74 , A61F2/02
CPC分类号： A61K31/46 , A61K31/137 , A61K31/221 , A61K31/4178 , A61K31/728 , A61K31/765 , A61K9/0048 , A61L31/042 , A61L31/048 , A61L31/16 , A61F9/00 , A61L2300/402 , A61L2300/45 , A61L2430/16
摘要： The present invention relates to compositions which maintain the structural integrity of the anterior chamber of the eye during ophthalmologic surgery, thereby protecting the tissues that form and line the anterior segment from potential damage and simultaneously providing sustained delivery of pharmaceuticals, including miotic, mydriatic, or anesthetic agents.
摘要翻译：本发明涉及在眼科手术期间保持眼睛前房的结构完整性的组合物，从而保护形成和排列前段的组织免受潜在的损害并同时提供药物的持续递送，包括缩瞳，散瞳或麻醉剂。

9. 发明申请

US20130150451A1 BIOCIDAL COMPOSITIONS AND METHODS OF USING THE SAME 有权
标题翻译：生物组合物及其使用方法
公开(公告)号：US20130150451A1
公开(公告)日：2013-06-13
申请号：US13313880
申请日：2011-12-07
申请人： Joseph C. Salamone , Ann Beal Salamone
发明人： Joseph C. Salamone , Ann Beal Salamone
IPC分类号： A01N37/52 , A01P1/00
CPC分类号： A01N47/44 , A61K31/155 , Y02A50/473 , A01N31/02 , A01N37/12
摘要： An antimicrobial composition with synergistic biocidal activity is described which comprises at least one antimicrobial polymeric biguanide and at least one antimicrobial vicinal diol, said vicinal diol comprises at least one monoalkyl glycol, monoalkyl glycerol, or monoacyl glycerol, to diminish or eliminate biofilm communities. Such synergistic interaction is effective in wound treatment, particularly for chronic wounds, burns and battlefield-induced wounds, as well as for disinfecting non-biological surfaces. The antimicrobial composition can also be prepared as viscous solutions or as gels. The antimicrobial composition may be added to a substrate and dried, such as to a catheter, or to a foam, or to a fiber wound dressing, or coated as a viscous solution or gel upon such devices, to provide controlled release antimicrobial activity.
摘要翻译：描述了具有协同杀生物活性的抗微生物组合物，其包含至少一种抗微生物聚合双胍和至少一种抗微生物连位二醇，所述连位二醇包含至少一种单烷基二醇，单烷基甘油或单酰基甘油，以减少或消除生物膜群落。这种协同相互作用在伤口治疗中是有效的，特别是对于慢性伤口，烧伤和战场引起的伤口以及用于消毒非生物表面。抗微生物组合物也可以制备成粘稠溶液或凝胶。抗微生物组合物可以加入到基质中并干燥，例如导管，或泡沫，或纤维伤口敷料，或在这种装置上作为粘性溶液或凝胶涂覆，以提供受控释放的抗微生物活性。

10. 发明申请

US20120208974A1 AMPHIPHILIC PRESSURE SENSITIVE ADHESIVES FOR HUMAN SKIN ADHESION 有权
标题翻译：人体皮肤粘合剂的压力敏感性粘合剂
公开(公告)号：US20120208974A1
公开(公告)日：2012-08-16
申请号：US13210038
申请日：2011-08-15
申请人： Mahesh Sambasivam , Xiang Yu , Joseph C. Salamone , Ann Beal Salamone
发明人： Mahesh Sambasivam , Xiang Yu , Joseph C. Salamone , Ann Beal Salamone
IPC分类号： C09J133/26 , C09J177/02
CPC分类号： C09J133/26 , C08F220/18 , C09J133/08 , C09J139/04 , C08F220/56
摘要： The present invention relates to amphiphilic pressure sensitive adhesives, specifically, pressure sensitive adhesives with amphiphilic copolymers which improve adhesion under moist environment. The amphiphilic copolymers comprise at least one hydrophobic acrylic monomer or oligomer and at least one hydrophilic or amphiphilic monomer or oligomer. The present invention also relates to the use of such adhesives in securing medical devices to human skin.
摘要翻译：本发明涉及两亲压敏粘合剂，具体地说，涉及在潮湿环境下改善粘合性的两亲共聚物的压敏粘合剂。两亲共聚物包含至少一种疏水性丙烯酸单体或低聚物和至少一种亲水或两亲性单体或低聚物。本发明还涉及这种粘合剂在将医疗装置固定在人体皮肤上的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式